EVALUATION AND COMPARISON OF LIVER MARKERS IN ACUTE LIVER FAILURE VS CHRONIC LIVER FAILURE IN DISTRICT FAISALABAD: A CROSS-SECTIONAL STUDY
DOI:
https://doi.org/10.71000/f2d0tp38Keywords:
Alanine Aminotransferase, Alkaline Phosphatase, Aspartate Aminotransferase, Bilirubin, Gamma-Glutamyl Transferase, Liver Failure, Liver Function TestsAbstract
Background: Liver failure is a life-threatening clinical condition resulting from the inability of the liver to maintain its metabolic, synthetic, and detoxification functions. Acute liver failure presents with sudden and severe hepatic dysfunction, whereas chronic liver failure develops gradually following prolonged liver injury. Biochemical liver markers remain central to differentiating these entities and assessing disease severity, yet comparative local data remain limited.
Objective: To evaluate and compare biochemical liver markers in patients with acute liver failure and chronic liver failure in order to identify characteristic laboratory patterns that aid clinical differentiation.
Methods: A retrospective cross-sectional study was conducted at Allied Hospital Faisalabad. A total of 100 patients aged 20–60 years were included, comprising 44 males and 56 females. Serum samples were analyzed using a Microlab 300 semi-automated chemistry analyzer. Measured parameters included alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transferase, total bilirubin, direct bilirubin, and indirect bilirubin. Standard reagent kits and manufacturer-recommended protocols were followed. Data were summarized using descriptive and comparative analysis.
Results: Acute liver failure showed markedly elevated aminotransferases, with mean ALT values of 370 U/L in males and 360 U/L in females, compared with 120 U/L and 110 U/L in chronic liver failure, respectively. Mean AST levels were also higher in acute liver failure (360 U/L in males, 355 U/L in females) than in chronic liver failure (135 U/L and 110 U/L). Cholestatic markers demonstrated variable patterns, with ALP values reaching 375 U/L in females with acute liver failure and 252 U/L in males with chronic disease. Mean GGT levels were higher in acute liver failure (200 U/L in males, 180 U/L in females) compared with chronic liver failure. Total bilirubin levels were elevated in both groups but were higher in acute liver failure, reaching 4.5 mg/dL in females. Direct bilirubin predominated in acute cases, whereas indirect bilirubin was relatively higher in chronic liver failure.
Conclusion: Distinct biochemical patterns were observed between acute and chronic liver failure, with acute disease characterized by pronounced hepatocellular injury and chronic disease showing sustained cholestatic and metabolic alterations. These findings support the clinical utility of liver markers in differentiating liver failure types and guiding early diagnosis and management.
References
Hassan HM, Liang X, Xin J, Lu Y, Cai Q, Shi D, et al. Thrombospondin 1 enhances systemic inflammation and disease severity in acute-on-chronic liver failure. BMC Med. 2024;22(1):95.
Aghdassi A, Schwedhelm E, Atzler D, Nauck M, Kühn JP, Kromrey ML, et al. The relationship between homoarginine and liver biomarkers: a combination of epidemiological and clinical studies. Sci Rep. 2023;13(1):5230.
Demirors B, Shekouhi R, Jimenez PB, Yadav A, Chiriboga G, Mahesh VA, et al. Redefining the albumin-bilirubin score: Predictive modeling and multidimensional integration in liver and systemic disease. World J Gastroenterol. 2025;31(34):110602.
Wang D, Wang X, Mu J, Kuang Z, Zhang J, Lu X, et al. Prognostic indicators and outcome in patients with acute liver failure, sepsis and with and without shock: a retrospective cohort study. Ann Med. 2025;57(1):2438833.
Jiang H, Zhao Z, Cui S, Kong X, Jiang X. Prognostic factors for mortality in patients with acute-on-chronic liver failure. Eur J Gastroenterol Hepatol. 2025;37(7):833-43.
Camera A, Islam T, Parvan R, Pischke SE, Silva GJJ, Stensløkken KO. Prognostic and diagnostic biomarkers in liver transplantation: A systematic review and meta-analysis. Liver Transpl. 2025;31(12):1499-510.
Yang Z, Ma X, Zhou X, Huang D, Wang Y, Li X, et al. Predictive performance of eLIFT for liver inflammation and fibrosis in chronic liver diseases. Int J Med Sci. 2021;18(15):3599-608.
Zhou H, Li H, Deng G, Wang X, Zheng X, Chen J, et al. A novel model for identifying infections in patients with AoCLD: a nationwide, multicenter, prospective cohort study. Qjm. 2025;118(7):489-500.
Kern AE, Pereyra D, Santol J, Ammann M, Kim S, Huber FX, et al. MicroRNA based Prediction of Posthepatectomy Liver Failure and Mortality Outperforms Established Markers of Preoperative Risk Assessment. Ann Surg Oncol. 2025;32(9):6283-94.
Kim WR, Mannalithara A, Heimbach JK, Kamath PS, Asrani SK, Biggins SW, et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021;161(6):1887-95.e4.
Kowdley KV, Victor DW, 3rd, MacEwan JP, Nair R, Levine A, Hernandez J, et al. Longitudinal Relationship Between Elevated Liver Biochemical Tests and Negative Clinical Outcomes in Primary Biliary Cholangitis: A Population-Based Study. Aliment Pharmacol Ther. 2025;61(11):1775-84.
Zelber-Sagi S, O'Reilly-Shah VN, Fong C, Ivancovsky-Wajcman D, Reed MJ, Bentov I. Liver Fibrosis Marker and Postoperative Mortality in Patients Without Overt Liver Disease. Anesth Analg. 2022;135(5):957-66.
Kishi Y, Vauthey JN. Issues to be considered to address the future liver remnant prior to major hepatectomy. Surg Today. 2021;51(4):472-84.
Hui WF, Deep A. Interpreting liver function markers in children on continuous renal replacement therapy for acute liver failure. Eur J Pediatr. 2025;184(11):675.
McGill MR. From fructose to the future: liver disease biomarkers and their prognostic value in acute liver failure. Crit Rev Clin Lab Sci. 2025;62(5):386-403.
Zhang Y, Cai Y, Tu B, Yang X, Hu J, Zhang H. Effect of CD163 Modification on Glucocorticoid-Related Mortality in Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure. Altern Ther Health Med. 2023;29(8):850-5.
Galasso L, Esposto G, Mignini I, Ainora ME, Zocco MA. Decoding prognosis in dengue-induced hepatitis: Model for end-stage liver disease vs albumin-bilirubin for predicting liver failure and survival. World J Gastroenterol. 2025;31(16):102778.
Perez Ruiz de Garibay A, Kortgen A, Leonhardt J, Zipprich A, Bauer M. Critical care hepatology: definitions, incidence, prognosis and role of liver failure in critically ill patients. Crit Care. 2022;26(1):289.
Liu Y, Wu Y, He S. Clinical value of microRNA-130a as a marker of acute liver failure and its involvement in disease development. Hum Immunol. 2024;85(6):111173.
Marañón P, Isaza SC, Rey E, Rada P, García-García Y, Dear JW, et al. BMP6 participates in the molecular mechanisms involved in APAP hepatotoxicity. Arch Toxicol. 2025;99(3):1187-202.
Castillo-Castañeda SM, Cordova-Gallardo J, Rivera-Espinosa L, Chavez-Pacheco JL, Ramírez-Mejía MM, Méndez-Sánchez N. Bilirubin Molecular Species Play an Important Role in the Pathophysiology of Acute-on-Chronic Liver Failure. Int J Mol Sci. 2024;25(15).
Xie Y, Lin L, Sun C, Chen L, Lv W. Association between serum alkaline phosphatase and clinical prognosis in patients with acute liver failure following cardiac arrest: a retrospective cohort study. Eur J Med Res. 2024;29(1):453.
Wang Z, Lv H, Luo P, Wang J, Wang N, Zhu H, et al. ANXA3 hypomethylation as a prognostic biomarker in hepatitis B virus-related acute-on-chronic liver failure. Ann Med. 2025;57(1):2595332.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Hafiz Muhammad Siddiq, Muhammad Ahmad, Moeez Khalid, Fardous, Maham Fatima Awan, Kinza Tariq, Saadia Momal Zafar, Muhammad Suleman, Rafia Anwer (Author)

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.





